Flotetuzumab

DB15223Investigational

Flotetuzumab is under investigation in clinical trial NCT02152956 (Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS).

Mechanism: Pharmacologically active on Interleukin-3 receptor subunit alpha
Curator reviewed
Code names: RES234

Resolves to

Compound

UNII0AHT0IC02GCAS1664355-28-5

Targets

P26951IL3RA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Flotetuzumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account